Objective: In order to compare the efficacy and safety of transurethral 1470nm laser and Greenlight Laser in the treatment of benign prostatic hyperplasia. Methods: 204 patients with benign prostatic hyperplasia admitted to the former Navy General Hospital from January 2017 to September 2019 were used to investigate. Among them, 103 patients were treated by transurethral 1470nm laser vaporization of prostate, and the other 101 patients were treated by transurethral Greenlight Laser vaporization of prostate. Blood loss during operation, operation time, postoperative bladder irrigation time, postoperative indwelling catheter time, postoperative hospital stay and complications were compared between the two groups. The International Prostate Symptom Score (I-PSS), Quality of Life Score (QoL) and Maximum Urinary Flow Rate (Qmax) were statistically compared before operation, 3 months after operation and 1 year after operation. Results: The results show that the comparison between group is blood loss during operation (14.7±7.7 vs. 16.4±8.8 ml, p>0.05), operation time (89.1±38.9 vs. 82.4±39.6 min, p>0.05), postoperative bladder irrigation time (20.6±4.0 vs. 22.0±6.4 h, p>0.05), postoperative indwelling catheter time (71.2±17.2 vs. 73.7±21.5 h, p>0.05), postoperative hospital stay(5.0±1.0 vs. 5.3±1.2 d, p>0.05) and complications [2.9 % (3/103) vs. 4.0 % (4/101) , p>0.05]. Preoperative and postoperative 3 months, 1 year after operation I-PSS, QoL and Qmax were compared between groups have no statistical difference (p > 0.05). Group comparison before and after the operation there are significant differences (p < 0.01). Conclusions: It is concluded that transurethral 1470nm laser vaporization of prostate and transurethral Greenlight Laser vaporization of prostate to treat benign prostatic hyperplasia with a consistent safety and therapeutic effects.